Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$1.73
−$0.04 · -2.26%
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Previous close
$1.73
−$0.04 · -2.26%
Regular session · ET · Market data may be delayed.
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Day range
Current $1.73
52-week range
Current $1.73
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
45
Mixed
Risk
60
Elevated Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Day range
Current $1.73
52-week range
Current $1.73
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 757.26M EUR | 796.97M EUR | 781.43M EUR | 751.45M EUR | 618.03M EUR |
| Cost of goods sold | 694.6M EUR | 682.09M EUR | 606.38M EUR | 577.38M EUR | 466.49M EUR |
| Gross profit | 62.66M EUR | 114.88M EUR | 175.05M EUR | 174.07M EUR | 151.54M EUR |
| Research and development | 74.33M EUR | 50.86M EUR | 68.53M EUR | 76.64M EUR | 65.7M EUR |
| Selling, general, and administrative | 123.65M EUR | 188.2M EUR | 169.61M EUR | 156.19M EUR | 105.45M EUR |
| Operating expenses | 197.97M EUR | 257.4M EUR | 222.56M EUR | 153.22M EUR | 110.55M EUR |
| Interest income | 4.25M EUR | 2.44M EUR | 9.26M EUR | 8.34M EUR | 2.27M EUR |
| Interest expense | 13.87M EUR | 11.7M EUR | 11.74M EUR | 13.15M EUR | 9.25M EUR |
| Depreciation and amortization | 95.55M EUR | 101.62M EUR | 92.98M EUR | 83.2M EUR | 70.4M EUR |
| Operating income | −135.31M EUR | −142.52M EUR | −47.51M EUR | 20.85M EUR | 41M EUR |
| Net income | −99.43M EUR | −196.08M EUR | −83.91M EUR | −175.66M EUR | 215.51M EUR |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.00
73.41% upsideCash distributions grouped by calendar year; partial years are marked.
$0.5412
2018 complete year-6.0% since 2017
$0.576
2,017
$0.5412
2,018
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jan 11, 2019 | $0.2888Monthly | — | — |
Dividend | Dec 12, 2018 | $0.1804Monthly | — | — |
Dividend | Nov 8, 2018 | $0.1804Monthly | — | — |
Dividend | Oct 10, 2018 | $0.1804Monthly | — | — |
Dividend | Sep 13, 2018 | $0.1804Monthly | — | — |
Dividend | Aug 10, 2018 | $0.1804Monthly | — | — |
Ex-dividend Jan 11, 2019
$0.2888
Monthly
Ex-dividend Dec 12, 2018
$0.1804
Monthly
Ex-dividend Nov 8, 2018
$0.1804
Monthly
Ex-dividend Oct 10, 2018
$0.1804
Monthly
Ex-dividend Sep 13, 2018
$0.1804
Monthly
Ex-dividend Aug 10, 2018
$0.1804
Monthly
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
